Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline
- Conditions
- Brain Injuries
- Interventions
- Drug: Normal SalineDrug: hypertonic saline mixed with dextran
- Registration Number
- NCT00878631
- Lead Sponsor
- Unity Health Toronto
- Brief Summary
This clinical trial will evaluate the ease of conducting a randomized trial on patients with severe head injury who are cared for by paramedics in the out of hospital setting. The trial will compare two different kinds of fluids that are commonly used to elevate blood pressure and minimize the impact of the brain injury. The two solutions are a salt solution of different concentrations. One is a normal saline solution similar to the consistency of human blood and the other is a higher concentration mixed with a sugar that helps to keep the solution in the blood stream longer. This study is conducted without patient consent at the time of the study enrolment. The study will report on whether this trial is feasible in the out of hospital setting before launching into a larger definitive trial.
- Detailed Description
The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT) is a randomized, placebo-controlled out of hospital trial of blunt trauma patients with head injuries. The study compares a group receiving normal saline according to a paramedic's protocol, with a treatment group receiving a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 (RescueFlow BioPhausia AB, Stockholm Sweden).
The primary objective of this study is to report feasibility in accordance with the methodology described by Lancaster and Dodds\*, specifically addressing:
1. baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial.
2. randomization compliance rate.
3. ease of protocol implementation in the out-of-hospital setting.
4. adverse rate of HSD infusion.
The secondary objectives include measuring the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulating the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome and clinical response to HSD intervention; evaluating effects of HSD on brain atrophy post-injury and neurocognitive and neuropsychological outcomes.
\*Lancaster, G.A., S. Dodd, and P.R. Williamson, Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract, 2004. 10(2): p. 307-12.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 113
- Age ≥ 16;
- Initial assessment of GCS 8 or less;
- Blunt traumatic mechanism of injury.
- Known pregnancy;
- Primary injury penetrating;
- VSA prior to randomization;
- Previous Intravenous therapy ≥ 50 ml;
- Time interval between arrival at scene and intravenous access exceeds four hours;
- Amputation above wrist or ankle;
- Any burn (thermal, chemical, electrical, radiation)
- Suspected hypothermia;
- Asphyxia (strangulation, hanging, choking, suffocation, drowning)
- Fall from height ≤ 1m or ≤ 5 Stairs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Normal Saline Normal Saline infusion of 250 ccs of Normal Saline within 4 hours of the accident 2 - hypertonic saline mixed with dextran hypertonic saline mixed with dextran a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 infused within 4 hours of the accident
- Primary Outcome Measures
Name Time Method baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial survival at 48 hours, hospital discharge, 30 days and 4 months randomization compliance rate duration of enrolment ease of protocol implementation in the out-of-hospital setting duration of study adverse event rate of hypertonic saline dextran infusion duration of study
- Secondary Outcome Measures
Name Time Method neurocognitive outcomes at discharge (cerebral performance category) and at 4 months (functional independence measure, disability rating scale, Glasgow Outcome Scale and Glasgow outcome Scale Extended discharge and at 4 months post incident neuropsychological outcomes including learning and memory, working memory, executive function, language function, visuospatial function, speed of processing and Beck Depression Scale. A focused attention reaction time test was added to 12 month testing. at 4 and 12 months post incident magnetic resonance imaging to evaluate effects of HSD on brain atrophy post-injury 4 months post incident the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulation the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome samples taken within 48 hours of incident
Trial Locations
- Locations (2)
Sunnybrook Health Sciences Center
🇨🇦Toronto, Ontario, Canada
St Michael's Hospital
🇨🇦Toronto, Ontario, Canada